Shortly after my recent post, “How the Backlash to Oregon’s Plan to Taper Opioids with Integrative Approaches Missed the Mark”, I received an e-note from national pain leader Sean Mackey, MD, PhD. The letterhead of the chief of the division of pain medicine at Stanford University and co-chair of the US HHS National Pain Strategy was the vehicle through which Mackey and 100 co-signers successfully campaigned for the Oregon Health Authority to prevent forced tapering “of certain patient populations.” Mackey wrote that he presumed we had shared interests in bettering care, yet he thought there was a harmful “negativity” in my article: “May I suggest rather than a ‘missed opportunity’ message, you could easily frame it as ‘forced opioid tapering defeated – here is what we need to do next …'”
For the past half decade, the Academy of Integrative Pain Management (AIPM) has carried the policy mantle for integrative pain treatment into ever more influential places. The beacons were the 2017 and 2018 Integrative Pain Care Policy Congress. The most recent convened 70 stakeholder organizations, including key payers and federal agencies. On January 29, 2019, AIPM announced that it has ceased operations. Amidst the present opportunities for transforming pain treatment, the integrative pain field lost its engine. Oddly, the very challenges to the pharma industry in the center of the dominant pain model were part of AIPM’s undoing.